Skip to main content
Erschienen in: Clinical Drug Investigation 5/2017

01.05.2017 | Original Research Article

Effect of N-Acetylcysteine on Mortality and Liver Transplantation Rate in Non-Acetaminophen-Induced Acute Liver Failure: A Multicenter Study

verfasst von: Samar K. Darweesh, Mona F. Ibrahim, Mahmoud A. El-Tahawy

Erschienen in: Clinical Drug Investigation | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction and Aim

Previous studies and systematic reviews have not provided conclusive evidence on the effect of N-acetylcysteine (NAC) in non-acetaminophen-induced acute liver failure (NAI-ALF). We aimed to study the value of intravenous NAC in reducing liver transplantation and mortality in NAI-ALF.

Patients and Methods

In a prospective, multicenter, observational study, acute liver failure patients without clinical or historical evidence of acetaminophen overdose were enrolled. NAC infusion (in empirical dose) was given as 150 mg/kg in 100 ml dextrose 5% over half an hour, then 70 mg/kg in 500 ml dextrose 5% over 4 h, then 70 mg/kg in 500 ml dextrose 5% over 16 h. Thereafter continuous infusion was administered over 24 h of 150 mg/kg in 500 ml dextrose 5% until up to two consecutive normal international normalized ratios (INRs) were obtained. Our endpoints were recovery, transplantation, or death. The primary outcome of the study was to assess reduction in mortality or liver transplantation. The secondary outcome was the evaluation of other clinical outcomes (length of ICU and hospital stays, organ system failure, and hepatic encephalopathy).

Results

The study included a total of 155 adults; the NAC group (n = 85) were given NAC between January 2011 to December 2013 and the control group (n = 70) were not given NAC and were included from files dating between 2010 and 2011. Both groups (before NAC) were comparable with regard to etiology, age, sex, smoking, presence of co-morbidities, encephalopathy, liver profile, and INR. The success rate (transplant-free survival) in the NAC group was 96.4%. While in the control group, 17 patients (23.3%) recovered and 53 (76.6%) did not recover, of these 37 (53.3%) had liver transplantation and 16 (23.3%) died (p < 0.01). The NAC group had significantly shorter hospital stays (p < 0.001), less encephalopathy (p = 0.02), and less bleeding (p < 0.01) than the control group. The control group reported a higher ICU admission (p = 0.01) rate and abnormal creatinine and electrolytes (p = 0.002, p < 0.01, respectively). Liver profile and INR (after NAC infusion) differed significantly between the two groups with regard to bilirubin (increased in controls, p = 0.02), AST and INR (decreased in NAC group, p < 0.001 for both), but the ALT decrease showed no statistical significance between the two groups.

Conclusions

When administered on admission, intravenous NAC caused a reduction in NAI-ALF mortality and need for transplantation. NAC decreased encephalopathy, hospital stay, ICU admission, and failure of other organs.
Literatur
2.
Zurück zum Zitat O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342(8866):273–5.CrossRefPubMed O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342(8866):273–5.CrossRefPubMed
3.
4.
Zurück zum Zitat Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: a 48-h intravenous N-acetylcysteine treatment protocol. Ann Emerg Med. 1991;20(10):1058–63.CrossRefPubMed Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: a 48-h intravenous N-acetylcysteine treatment protocol. Ann Emerg Med. 1991;20(10):1058–63.CrossRefPubMed
5.
Zurück zum Zitat Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976–1985). N Engl J Med. 1988;319(24):1557–62.CrossRefPubMed Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976–1985). N Engl J Med. 1988;319(24):1557–62.CrossRefPubMed
6.
Zurück zum Zitat Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol. 1989;36(2):127–31.CrossRefPubMed Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol. 1989;36(2):127–31.CrossRefPubMed
7.
Zurück zum Zitat Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003;60(1):6–20.CrossRefPubMed Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003;60(1):6–20.CrossRefPubMed
8.
Zurück zum Zitat Harrison P, Wendon J, Williams R. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. Hepatology. 1996;23(5):1067–72.CrossRefPubMed Harrison P, Wendon J, Williams R. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. Hepatology. 1996;23(5):1067–72.CrossRefPubMed
9.
Zurück zum Zitat Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324(26):1852–7.CrossRefPubMed Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324(26):1852–7.CrossRefPubMed
10.
Zurück zum Zitat Ytrebo LM, Korvald C, Nedredal GI, Elvenes OP, Nielsen Grymyr OJ, Revhaug A. N-Acetylcysteine increases cerebral perfusion pressure in pigs with fulminant hepatic failure. Crit Care Med. 2001;29(10):1989–95.CrossRefPubMed Ytrebo LM, Korvald C, Nedredal GI, Elvenes OP, Nielsen Grymyr OJ, Revhaug A. N-Acetylcysteine increases cerebral perfusion pressure in pigs with fulminant hepatic failure. Crit Care Med. 2001;29(10):1989–95.CrossRefPubMed
11.
Zurück zum Zitat Peristeris P, Clark BD, Gatti S, Faggioni R, Mantovani A, Mengozzi M, et al. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell Immunol. 1992;140:390–9.CrossRefPubMed Peristeris P, Clark BD, Gatti S, Faggioni R, Mantovani A, Mengozzi M, et al. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell Immunol. 1992;140:390–9.CrossRefPubMed
12.
Zurück zum Zitat Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-Acetylcysteine in acute hepatic failure (non-paracetamol induced). Hepatogastroenterology. 2000;47(33):786–9.PubMed Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-Acetylcysteine in acute hepatic failure (non-paracetamol induced). Hepatogastroenterology. 2000;47(33):786–9.PubMed
13.
Zurück zum Zitat Katoonizadeh A, Decaestecker J, Wilmer A, Aerts R, Verslype C, Vansteenbergen W, et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int. 2007;27(3):329–34.CrossRefPubMed Katoonizadeh A, Decaestecker J, Wilmer A, Aerts R, Verslype C, Vansteenbergen W, et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int. 2007;27(3):329–34.CrossRefPubMed
14.
Zurück zum Zitat Escorsell A, Mas A, de la Mata M. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl. 2007;13(10):1389–95.CrossRefPubMed Escorsell A, Mas A, de la Mata M. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl. 2007;13(10):1389–95.CrossRefPubMed
15.
Zurück zum Zitat Sklar GE, Subramaniam M. Acetylcysteine treatment for non-acetaminophen-induced acute liver failure. Ann Pharmacother. 2004;38(3):498–500 Epub 2004 Jan 12.CrossRefPubMed Sklar GE, Subramaniam M. Acetylcysteine treatment for non-acetaminophen-induced acute liver failure. Ann Pharmacother. 2004;38(3):498–500 Epub 2004 Jan 12.CrossRefPubMed
17.
Zurück zum Zitat Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856–86.CrossRefPubMedPubMedCentral Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856–86.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Sales I, Dzierba AL, Smithburger PL, Rowe D, Kane-Gill SL. Use of acetylcysteine for non-acetaminophen-induced acute liver failure. Ann Hepatol. 2013;12(1):6–10.PubMed Sales I, Dzierba AL, Smithburger PL, Rowe D, Kane-Gill SL. Use of acetylcysteine for non-acetaminophen-induced acute liver failure. Ann Hepatol. 2013;12(1):6–10.PubMed
20.
Zurück zum Zitat Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in “non-acetaminophen” acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015;39(5):594–9. doi:10.1016/j.clinre.2015.01.003 Epub 2015 Feb 26.CrossRefPubMed Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in “non-acetaminophen” acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015;39(5):594–9. doi:10.​1016/​j.​clinre.​2015.​01.​003 Epub 2015 Feb 26.CrossRefPubMed
21.
Zurück zum Zitat Chughlay MF, Kramer N, Spearman CW, Werfalli M, Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. Br J Clin Pharmacol. 2016;. doi:10.1111/bcp.12880 [Epub ahead of print].PubMed Chughlay MF, Kramer N, Spearman CW, Werfalli M, Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. Br J Clin Pharmacol. 2016;. doi:10.​1111/​bcp.​12880 [Epub ahead of print].PubMed
23.
Zurück zum Zitat Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282–98.PubMed Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282–98.PubMed
24.
Zurück zum Zitat Zwingmann C, Bilodeau M. Metabolic insights into the hepato-protective role of N-acetylcysteine in mouse liver. Hepatology. 2006;43:454–63.CrossRefPubMed Zwingmann C, Bilodeau M. Metabolic insights into the hepato-protective role of N-acetylcysteine in mouse liver. Hepatology. 2006;43:454–63.CrossRefPubMed
25.
Zurück zum Zitat Pitari G, Dupre S, Spirito A, Antonini G, Amicarelli F. Hypotaurine protection on cell damage by singlet oxygen. Adv Exp Med Biol. 2000;483:157–62.CrossRefPubMed Pitari G, Dupre S, Spirito A, Antonini G, Amicarelli F. Hypotaurine protection on cell damage by singlet oxygen. Adv Exp Med Biol. 2000;483:157–62.CrossRefPubMed
26.
Zurück zum Zitat Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol. 1998;36:277–85.CrossRefPubMed Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol. 1998;36:277–85.CrossRefPubMed
27.
Zurück zum Zitat Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli-Vergani G, Dhawan A. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl. 2008;14(1):25–30.CrossRefPubMed Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli-Vergani G, Dhawan A. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl. 2008;14(1):25–30.CrossRefPubMed
28.
Zurück zum Zitat Gunduz H, Karabay O, Tamer A, Özaras R, Mert A, Tabak ÖF. N-acetylcysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003;9(12):2698–700.CrossRefPubMedPubMedCentral Gunduz H, Karabay O, Tamer A, Özaras R, Mert A, Tabak ÖF. N-acetylcysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003;9(12):2698–700.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Squires RH, Dhawan A, Alonso E, Narkewicz MR, Shneider BL, Rodriguez-Baez N, et al. Intravenous N-acetylcysteine in pediatric patients with non-acetaminophen acute liver failure: a Placebo-Controlled Clinical Trial. Hepatology. 2013;57(4):1542–9. doi:10.1002/hep.26001.CrossRefPubMedPubMedCentral Squires RH, Dhawan A, Alonso E, Narkewicz MR, Shneider BL, Rodriguez-Baez N, et al. Intravenous N-acetylcysteine in pediatric patients with non-acetaminophen acute liver failure: a Placebo-Controlled Clinical Trial. Hepatology. 2013;57(4):1542–9. doi:10.​1002/​hep.​26001.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–9.CrossRefPubMed Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–9.CrossRefPubMed
Metadaten
Titel
Effect of N-Acetylcysteine on Mortality and Liver Transplantation Rate in Non-Acetaminophen-Induced Acute Liver Failure: A Multicenter Study
verfasst von
Samar K. Darweesh
Mona F. Ibrahim
Mahmoud A. El-Tahawy
Publikationsdatum
01.05.2017
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 5/2017
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-017-0505-4

Weitere Artikel der Ausgabe 5/2017

Clinical Drug Investigation 5/2017 Zur Ausgabe